EUVIMEDEUVIMED entdecken
Crossref

Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma

Jiangping Yang, Liujie Qin, Shouchang Zhou, Jixing Li, Yu Tu, Minfeng Mo, Xuenian Liu, Jinglun Huang, Xiumei Qin, Aijun Jiao, Wei Wei, Peilin Yang

Journal of Ethnopharmacology · 2024-04 · 323 · 117667

DOI: 10.1016/j.jep.2023.117667 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2024-04. Verfasst von Jiangping Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Nasopharyngeal Neoplasms, Stephania, Benzylisoquinolines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Guangxi Medical University, Middle-aged and Young Teachers' Basic Ability Promotion Project of Guangxi, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ETHNOPHARMACOLOGICAL RELEVANCE: The Stephania cephalantha Hayata is an important traditional medicinal plant widely used in traditional medicine to treat cancer. Cepharanthine (CEP) was extracted from the roots of Stephania cephalantha Hayata. It has been found to exhibit anticancer activity in different types of cancer cells. Nevertheless, the activity of CEP against nasopharyngeal carcinoma (NPC) and its underlying mechanism warrant further investigation. AIMS OF THE STUDY: NPC is an invasive and highly metastatic malignancy that affects the head and neck region. This research aimed to investigate the pharmacological properties and underlying mechanism of CEP against NPC, aiming to offer novel perspectives on treating NPC using CEP. MATERIALS AND METHODS: In vitro, the pharmacological activity of CEP against NPC was evaluated using the CCK-8 assay. To predict and elucidate the anticancer mechanism of CEP against NPC, we employed network pharmacology, conducted molecular docking analysis, and performed Western blot experiments. In vivo validation was performed through a nude mice xenograft model of human NPC, Western blot and immunohistochemical (IHC) assays to confirm pharmacological activity and the mechanism. RESULTS: In a dose-dependent manner, the proliferation and clonogenic capacity of NPC cells were significantly inhibited by CEP. Additionally, NPC cell migration was suppressed by CEP. The results obtained from network pharmacology experiments revealed that anti-NPC effect of CEP was associated with 8 core targets, including EGFR, AKT1, PIK3CA, and mTOR. By performing molecular docking, the binding capacity of CEP to the candidate core proteins (EGFR, AKT1, PIK3CA, and mTOR) was predicted, resulting in docking energies of -10.0 kcal/mol for EGFR, -12.4 kcal/mol for PIK3CA, -10.8 kcal/mol for AKT1, and -8.6 kcal/mol for mTOR. The Western blot analysis showed that CEP effectively suppressed the expression of EGFR and the phosphorylation levels of downstream signaling proteins, including PI3K, AKT, mTOR, and ERK. After CEP intervention, a noteworthy decrease in tumor size, without inducing any toxicity, was observed in NPC xenograft nude mice undergoing in vivo treatment. Additionally, IHC analysis demonstrated a significant reduction in the expression levels of EGFR and Ki-67 following CEP treatment. CONCLUSION: CEP exhibits significant pharmacological effects on NPC, and its mechanistic action involves restraining the activation of the EGFR/PI3K/AKT pathway. CEP represents a promising pharmaceutical agent for addressing and mitigating NPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktNasopharyngeal NeoplasmsStephaniaBenzylisoquinolinesBenzodioxolesAnimalsMiceHumansNasopharyngeal CarcinomaMolecular Docking SimulationMice, NudePhosphatidylinositol 3-KinasesNetwork PharmacologyCell Line, TumorTOR Serine-Threonine KinasesClass I Phosphatidylinositol 3-KinasesErbB Receptors

Stichwörter der Autor:innen

CepharanthineMolecular dockingNasopharyngeal carcinomaNetwork pharmacology

Substanzen

cepharanthineProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesClass I Phosphatidylinositol 3-KinasesErbB ReceptorsBenzylisoquinolinesBenzodioxoles

Autor:innen und Institutionen

  • Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China.
  • School of Basic Medical Sciences, Guangxi Medical University, Nanning, 530021, China.
  • Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China.
  • Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China; Life Sciences Institute, Guangxi Medical University, Nanning, 530021, China. Electronic address: 807249683@qq.com.
  • Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China. Electronic address: 1016761237@qq.com.
  • Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China. Electronic address: yangpeilin@gxu.edu.cn.

Förderung

  • Guangxi Medical University
  • Middle-aged and Young Teachers' Basic Ability Promotion Project of Guangxi
  • China Postdoctoral Science Foundation
  • Science and Technology Department of Guangxi Zhuang Autonomous Region

Zitieren

APA

Yang, J., Qin, L., Zhou, S., Li, J., Tu, Y., Mo, M., Liu, X., Huang, J., Qin, X., Jiao, A., Wei, W., & Yang, P. (2024). Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma. Journal of Ethnopharmacology, 323, 117667. https://doi.org/10.1016/j.jep.2023.117667

Vancouver

Yang J, Qin L, Zhou S, Li J, Tu Y, Mo M, et al. Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma. Journal of Ethnopharmacology. 2024;323:117667. doi:10.1016/j.jep.2023.117667

BibTeX
@article{Yang2024,
  author = {Yang, Jiangping and Qin, Liujie and Zhou, Shouchang and Li, Jixing and Tu, Yu and Mo, Minfeng and Liu, Xuenian and Huang, Jinglun and Qin, Xiumei and Jiao, Aijun and Wei, Wei and Yang, Peilin},
  title = {Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma},
  journal = {Journal of Ethnopharmacology},
  year = {2024},
  volume = {323},
  pages = {117667},
  doi = {10.1016/j.jep.2023.117667}
}
Kostenlos starten →